Pracinostat - MEI Pharma

Drug Profile

Pracinostat - MEI Pharma

Alternative Names: SB-939

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator S*BIO
  • Developer Helsinn; MEI Pharma; S*BIO; University of Texas M. D. Anderson Cancer Center
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Myelofibrosis
  • Phase I Cancer

Most Recent Events

  • 01 Jun 2018 M.D. Anderson Cancer Center completes a phase II trial in Myelofibrosis (Combination therapy) in USA (PO) (NCT02267278)
  • 01 Jun 2018 Interim adverse events data from a phase II trial in Myelodysplastic syndrome released by MEI Pharma
  • 08 Feb 2018 Phase-I clinical trials in Cancer (In volunteers) in United Kingdom (PO) (NCT03495934)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top